Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 2-12 , May 2009

American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update

  • Salvatore L. Ruggiero, DMD, MD

      Affiliations

    • Associate Professor, Division of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine; Attending, Long Island Jewish Medical Center, New Hyde Park, NY; New York Center for Orthognathic and Maxillofacial Surgery, Lake Success, NY
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Ruggiero: Division of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, NY; New York Center for Orthognathic and Maxillofacial Surgery, 2001 Marcus Avenue, Lake Success, NY 11042
    • ,
  • Thomas B. Dodson, DMD, MPH

      Affiliations

    • Visiting Oral and Maxillofacial Surgeon and Director, Center for Applied Clinical Investigation, Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital; Associate Professor, Harvard School of Dental Medicine, Boston, MA
    • ,
  • Leon A. Assael, DMD

      Affiliations

    • Professor and Chairman, Oral and Maxillofacial Surgery, Oregon Health and Science University, Portland, OR
    • ,
  • Regina Landesberg, DMD, PhD

      Affiliations

    • Associate Professor, Division Oral Maxillofacial Surgery, Columbia University School of Dental and Oral Surgery, New York, NY
    • ,
  • Robert E. Marx, DDS

      Affiliations

    • Professor of Surgery and Chief, Division of Oral and Maxillofacial Surgery, University of Miami School of Medicine, Miami, FL
    • ,
  • Bhoomi Mehrotra, MD

      Affiliations

    • Section Head, Division of Medical Oncology, Long Island Jewish Medical Center, and Associate Professor of Clinical Medicine, Albert Einstein College of Medicine, New Hyde Park, NY

References 

  1. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  2. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95:297
  3. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled, clinical trials. J Clin Oncol. 2001;19:558
  4. Hortobagyi GN, Theriault RL, Porter L, et al. Protocol 19 Aredia Breast Cancer Study Group Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Eng J Med. 1996;335:1785
  5. Hortobagyi GN, Theriault RL, Lipton A, et al. Protocol 19 Aredia Breast Cancer Study Group Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998;16:2038
  6. Hillner BE, Ingle JN, Chelbowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042
  7. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458
  8. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879
  9. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind placebo-controlled trial. Cancer. 2004;100:2613
  10. Berenson JR, Lichtenstein A, Porter L, et al. Myeloma Aredia Study Group Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488
  11. Berenson JR, Lichtenstein A, Porter L, et al. Myeloma Aredia Study Group Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593
  12. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III double-blind, comparative trial. Cancer J. 2002;7:377
  13. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719
  14. United States Food and Drug Administration. Center for Drug Evaluation and Research: Reclast label information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistoryAccessed March 13, 2009
  15. Physicians' Desk Reference. (ed 57). Montvale, NJ: Medical Economics; 2003;
  16. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med. 1997;336:558
  17. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20:977
  18. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med. 2003;19:395
  19. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 2005;17:462
  20. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000;119:639
  21. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. Hepatology. 2005;42:762
  22. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189
  23. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic [Letter]. J Oral Maxillofac Surg. 2003;61:1115
  24. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  25. Estilo CL, Van Posnak CH, Williams T, et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study. J Clin Oncol. 2004;22:8088
  26. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis\osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567
  27. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83
  28. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182:417
  29. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions—Study of 20 cases [Letter]. Oral Oncol. 2006;42:327
  30. Pires FR, Miranda A, Cardoso ES, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis. 2005;11:365
  31. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753
  32. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med. 2005;353:100
  33. Hohnecker JA. Novartis “Dear Doctor” precautions added to label of Aredia and Zometa. 2004;September 24
  34. U.S. Food and Drug Administration Oncologic Drugs Advisory Committee. Combidex briefing information. http://www.fda.gov/ohms/dockets/ac/05/briefing/2005-4095b1.htmAccessed August 14, 2006
  35. U.S. Food and Drug Administration, Office of Drug Safety. Postmarketing safety review. www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_03_04-FDA-TAB3.pdf- 03-02-2005 -;Accessed August 14, 2006
  36. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(suppl 1):44
  37. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med. 2005;353:99
  38. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580
  39. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968
  40. Dimopoulos M, Kastritis E, Moulopoulos LA, et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate (American Society of Hematology Annual Meeting Abstracts). Blood. 2005;106:637
  41. Tosi P, Zamagni E, Cangini D, et al. Bisphosphonates and osteonecrosis of the jaws: Incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid (American Society of Hematology Annual Meeting Abstracts). Blood. 2005;106:3461
  42. Pozzi S, Marcheselli R, Sacchi S, et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw (American Society of Hematology Annual Meeting Abstracts). Blood. 2005;106:5057
  43. Cafro AM, Barbarano LA, Andriani A, et al. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: An Italian experience (American Society of Hematology Annual Meeting Abstracts). Blood. 2005;106:5152
  44. Zavras AI, Zhu S. Bisphosphonate are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis?. J Oral Maxillofac Surg. 2006;64:917
  45. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (ASCO Annual Meeting Proceedings (postmeeting edition)). J Clin Oncol. 2006;24:8528;http://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528Accessed August 14, 2006
  46. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809
  47. IMS Health, NPA Plus. Prescription drug information. http://www1.imshealth.com/ims/portal/front/articleC/0,2777,6599_40868211_40868264,00.htmlAccessed May 2006
  48. American Dental Association. Report of the Council of Scientific Affairs (Expert panel recommendations. Dental management of patients on oral bisphosphonate therapy). June 2006 http://www.ada.org/prof/resources/topics/osteonecrosis.aspAccessed June 29, 2006
  49. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415
  50. Ault A. Jaw necrosis affects 1 in 1,700 on oral bisphosphonates. Internal Medicine News. 2008;41:23;August 1
  51. Felsenberg D, Hoffmeister B. Necrosis of the jaw after high-dose bisphosphonate therapy. Deatsches Arzteblatt. 2006;103:3078
  52. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol. 2006;24:945
  53. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg. 2008;66:625
  54. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18:2015
  55. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826
  56. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Path Oral Radiol Endod. 2006;102:433
  57. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol. 2006;134:620
  58. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia. 2007;21:1545
  59. Khamaisi M, Regev E, Yarom N, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab. 2007;92:1172
  60. Sarasquete ME, Garcia-Sanz R, Marin L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood. 2008;112:2709
  61. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117
  62. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20:137
  63. Mehrotra B, Fantasia J, Ruggiero SL. Outcomes of bisphosphonate related osteonecrosis of the jaw (Importance of staging and management: A large single institution update). J Clin Oncol ASCO Meeting Abstracts. 2008;26(suppl):20526
  64. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of a low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100
  65. Ruggiero SL, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol Prac. 2006;2:7
  66. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc. 2005;136:1658
  67. American Association of Endodontists Position Statement: Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws. http://www.aae.org/dentalpro/guidelines.htmAccessed August 14, 2006
  68. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonates induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397
  69. Carlson ER. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(suppl 1):85
  70. Kademani D, Koka S, Lacy MQ, Rajkumar V. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc. 2006;81:1100
  71. Freiberger JJ. The utility of hyperbaric oxygen in the treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(suppl 1):96
  72. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: A report of two cases. J Oral Implantol. 2007;33:371
  73. National Institutes of Health. Funding opportunities and notices search results. http://grants.nih.gov/grants/guide/search_results.htm?text_curr=osteonecrosis&scope=pa-rfa&year=active&sort=&Search.x=10&Search.y=8Accessed November 19, 2008

 Approved by the Board of Trustees January 2009.

 Dr Ruggiero is a paid consultant for Amgen Corporation and Procter and Gamble and has received honorarium from Novartis; Dr Dodson states no financial arrangements or affiliations with a corporate organization or a manufacturer of products discussed in this article; Dr Assael is a paid consultant for Novartis and has received honoraria from Novartis and Merck; Dr Landesberg has received honoraria from Novartis Pharmaceutical Corporation; Dr Marx is a paid consultant for Medtronics and is a shareholder for Harvest Technologies. He receives royalties from Quintessence Publishing. Stryker, Synthes Maxillofacial, Biomet 3i, and Biomet Microfixation provide residency support at the Miami School of Medicine, although Dr Marx receives no personal monies from this funding. Dr Marx is a voluntary unpaid expert witness for Osborn LLC attorneys in litigation against Novartis Pharmaceuticals and Merck Co. Dr Mehrotra served as a consultant and on the Advisory Board and Speaker's Bureau for Novartis Pharmaceuticals.

PII: S0278-2391(09)00115-3

doi: 10.1016/j.joms.2009.01.009

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 2-12 , May 2009

Article Tools